Imo-8400 dose group 2    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
50Dermatomyositis1

50. Dermatomyositis    [ 157 clinical trials,   207 drugs,   (DrugBank: 76 drugs),   47 drug target genes,   142 drug target pathways]
Searched query = "Dermatomyositis", "Polymyositis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 157 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02612857
(ClinicalTrials.gov)
November 201518/11/2015Trial of IMO-8400 in Adult Patients With DermatomyositisA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With DermatomyositisDermatomyositisDrug: IMO-8400 Dose Group 1;Drug: IMO-8400 Dose Group 2;Drug: PlaceboIdera Pharmaceuticals, Inc.NULLCompleted18 Years75 YearsAll30Phase 2United States;Hungary;United Kingdom